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SUMMARY
Inflammatory bowel diseases are a group of chronic inflammatory conditions that affect 
gastrointestinal tract due to inapt and continuous immune activation in response to a myr-
iad of predisposing factors (most notably genetics, environmental impact and gut microbi-
ota composition). It has been shown that vitamin D status can also play a role in the disease 
pathogenesis, as its deficiency is commonly observed in two major forms of inflammatory 
bowel diseases – Crohn’s disease and ulcerative colitis. Mounting evidence supports the con-
cept of intricate relationship between gut dysbiosis and vitamin D metabolism, while subop-
timal levels of this vitamin have been linked to increased clinical disease relapse rates, inad-
equate response to drugs, as well as decreased quality of life in patients with Crohn’s disease 
and ulcerative colitis. Consequently, the pertinent question is whether increased vitamin D 
supplementation and (on a population level) food fortification may bring significant bene-
fit to the affected individuals. In this short review we discuss the synthesis, functions, status 
and food sources of vitamin D, appraise biotechnological facets of vitamin D status analysis 
and food fortification, and concentrate on novel developments in the field that describe its 
influence on intestinal microbiota and inflammatory bowel disease.
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INTRODUCTION
Vitamin D represents one of the four liposoluble vitamins in our body that has the abil-
ity to synthesise in the skin under the influence of ultraviolet (UV) radiation. It consists of 
two bioequivalent forms that are biologically inert and thus must be activated by undergo-
ing a process of double hydroxylation in the liver and kidneys (1). Calcidiol (25-hydroxy-vi-
tamin D) is an active form of vitamin D that circulates in the blood linked to globulin as a 
product of hydroxylation in the liver. Consequently, measuring concentrations of calcidiol 
is the optimal way to properly determine vitamin D status in our body. Biological half-life 
of calcidiol is 14 days and its normal concentration in blood is 75–150 nmol/L. Concentra-
tions less than 75 nmol/L indicate vitamin insufficiency, while its deficiency is considered 
when the concentrations are less than 50 nmol/L (2).
The most important role of vitamin D is to regulate absorption and homeostasis of 
calcium. In kidneys, calcidiol converts to calcitriol (1,25-hydroxy-vitamin D) after second 
hydroxylation process, and this bioequivalent form increases the absorption of calcium in 
the small intestine, while at the same time decreases the secretion of calcium by stimulat-
ing its resorption in distal renal tubules. Furthermore, calcitriol mobilises bone minerals so 
hypovitaminosis leads to osteomalacia in elderly (especially women) or rickets in young 
children (3). Only 15 % of dietary calcium and approx. 60 % of phosphorus are absorbed 
without vitamin D; conversely, its sufficiency raises calcium and phosphorus absorption 
by up to 40  and 80 %, respectively (4,5).
Production of vitamin D is influenced by UV radiation and exposure of the skin to sunlight. 
Therefore, skin is the main locale where its synthesis takes place. Areas above 40 degrees of 
south and north geographical latitude have low UV radiation, especially during winter time. 
D. LESKOVAR et al.: Vitamin D and Inflammatory Bowel Disease
October-December 2018 | Vol. 56 | No. 4456
Accordingly, people living in these areas are at greater risk of 
developing hypovitaminosis D (or vitamin D deficiency). Valua-
ble source of vitamin D is food, especially fish oil (such as tuna, 
salmon and cod fish); however, since the intake of vitamin D 
with food satisfies only 20 % of total daily needs, it is important 
to educate people on the importance of introducing foods rich 
in vitamin D in their quotidian meal plans (6).
As a steroid hormone, vitamin D binds to nuclear receptors 
and regulates expression of many genes (approx. 200) that in 
turn facilitate various pleiotropic health benefits reported for 
vitamin D (7). It has a wide range of effects – from insulin se-
cretion regulation to immune system modulation – making it 
more similar to hormones than other vitamins (8,9). Vitamin D 
has been implicated in a pathogenesis of various diseases such 
as diabetes type I, hypothyroidism, multiple sclerosis, systemic 
sclerosis and inflammatory bowel diseases (Crohn’s disease and 
ulcerative colitis). Studies have also demonstrated anticancer 
activity of vitamin D, with quite a strong correlation between 
higher dose of calcidiol and lower incidence of colorectal car-
cinoma (10). Spending reasonably more time in the sun and 
using dietary vitamin D may prevent or even treat a plethora 
of malignomas (such as colorectal, breast, prostate or oesoph-
ageal cancers). Therefore, it is reasonable to expect higher us-
age and prescription of vitamin D supplementation in the near 
future (11), and there could also be a rationale for vitamin D 
food fortification. The aim of this review is to assess whether 
such approaches could be beneficial for our gut microbiota, 
and whether they exhibit therapeutic effects in patients affect-
ed by inflammatory bowel diseases (IBD).
VITAMIN D STATUS
Studies have generally shown insufficient concentration 
of vitamin D in the population around the globe; it can be 
said that its deficiency affects 40–50 % of the populace (12). 
There are several risk factors that contribute to this issue of 
epidemic proportions. As we have already mentioned earlier, 
sunlight exposure and UV radiation affect the synthesis of vi-
tamin D in the skin. Due to this reason alone we can expect 
lower concentrations in areas with less sunlight during the 
year, especially in the winter and early spring period. Large 
meta-analysis in Saudi Arabia showed that 60 % of popula-
tion have deficiency of vitamin D – despite the fact this coun-
try has plenty of sunlight (13). Another risk factor is the type 
of skin. Darker pigmented skin contains more melanin, which 
acts as a natural protection from UV-B radiation. On the other 
hand, elderly individuals have thinner skin and lack 7-dehy-
drocholesterol, which is the main precursor of vitamin D (14).
Obese individuals and those with higher percentage of fat 
tissue are also prone to greater risk of hypovitaminosis. Nimri’s 
(15) study on the population of female college students aged 
18–26 recorded high frequency of vitamin D insufficiency in 
overweight and obese persons. A plausible explanation should 
be the enhanced uptake of vitamin D by adipose tissue; how-
ever, study suggests more complex and multifaceted relation-
ship (15). Furthermore, pregnant women and women who are 
breast feeding for a long time are at higher risk of developing 
vitamin deficiency. Due to the fact that hypovitaminosis occurs 
in both genders, we can safely assume that external factors play 
a major role (16). Patients with malabsorption or other gastro-
intestinal (GI) diseases are at greater risk, thus preventive usage 
of vitamin D is advised.
Europeans (including Scandinavian citizens) have the high-
est concentrations of vitamin D in the world (17). Different sun-
light exposure, dietary intake or use of vitamin D supplements 
may result in such favourable landscape. However, there are 
some ‘gaps’ on this map. In the northern parts of Italy research-
ers have identified 51.3 % postmenopausal women with vita-
min D insufficiency showing seasonal variations, the highest 
during winter-spring season (18). Croatia as a central Europe-
an country also revealed some differences. Study conducted 
by Laktasic-Zerjavic et al. (19) showed that 92.5 % of postmen-
opausal women, initially screened for osteoporosis, had inad-
equate vitamin D status. Additionally, hypovitaminosis D is a 
major problem in Croatia affecting entire population, not only 
risk groups (e.g. elderly or postmenopausal women). More than 
80 % of healthy young males have inadequate vitamin D sta-
tus, which could have significant long-term negative effects on 
health (20).
Generally speaking, vitamin D deficiency is more preva-
lent than previously thought. The Centers for Disease Control 
and Prevention (CDC) have shown that vitamin D sufficiency 
(defined by 25-hydroxy-vitamin D of at least 30 ng/mL, which 
is a very vague criterion) has basically halved – from 60 % in 
Caucasian and 10 % in African Americans during 1988–1994, 
to approx. 30 % in Caucasians and 5 % African Americans dur-
ing 2001–2004 (21). Additionally, severe vitamin D deficiency 
has been demonstrated in a higher percentage of individu-
als (21). Moreover, even when more conservative approach 
to vitamin D deficiency is used, a large number of patients 
encountered in clinical practice may be deficient in vitamin 
D (22). Even though risk factors for vitamin D deficiency are 
well known, it seems that the condition has increased over 
time – despite fortification of food in some countries (such as 
USA). The condition can be aggravated by decreased sunlight 
exposure, decreased oral intake and/or intestinal absorption 
of vitamin D in patients with IBD (6,16). Furthermore, one of 
the potential explanations is an increased awareness of this 
deficiency, which is why some practitioners test for vitamin D 
deficiency even in low-risk patients (23).
Nonetheless, it has been proposed that clinicians should 
pursue routine testing for hypovitaminosis D in patients with 
musculoskeletal symptoms, most notably myalgias, bone 
pain, and generalised weakness (22). This review aims to sug-
gest that the same approach may be considered for patients 
with significant gastrointestinal symptoms as well.
VITAMIN D FOOD SOURCES AND SUPPLEMENTS
The important source of vitamin D is food (8). If there is 
inadequate exposure to sunlight, it is pivotal to provide ad-
ditional source of vitamin D to satisfy the needs of our body. 
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in the US and European Union either vitamin D2 or vitamin D3 
can be used (24). In countries where food fortification with vi-
tamin D is permitted, foods such as margarine, milk products 
and breakfast cereals have become staple contributors to vi-
tamin D intake (24). Nonetheless, there is limited data in the 
literature regarding technological issues of food fortification 
with vitamin D.
Generally, fortification can be accomplished in different 
ways with variable efficiency. As mentioned before, in its na-
tive form vitamin D is fat soluble, although it can be prepared in 
water-soluble forms (e.g. emulsions) (24). Thus, adding vitamin 
D3 to cheese can be achieved by the addition of a commercial 
emulsion soluble in water, the addition of water-soluble vita-
min D in multilamellar liposomes, or by the homogenisation 
of liposoluble crystalline vitamin D in a cream portion used for 
the standardisation of milk for cheese production (30). As only 
small amounts of vitamin D are necessary to meet nutrient re-
quirements (for example, a suitable intake of vitamin D in adult 
women is 0.005 mg/day in comparison to 7 mg/day of vitamin 
E), low concentrations are added to foods – hence, ensuring 
sample homogeneity can be rather difficult (24).
Wagner et al. (31) have shown that vitamin D3 is quite sta-
ble during cheese processing and after more than one year 
of ripening at the temperature between 3 and 8 °C. Approxi-
mately half of vitamin D3 supplemented to the milk for cheese 
production is subsequently bound in the whey and, thus, in-
accessible for human biological processes. The added vitamin 
D3 is homogeneously distributed in cheese (31), and no loss 
is observed during fortified processed cheese manufacture or 
following storage for 9 months at 4–6 °C or 21–29 °C (32). Sim-
ilar characteristics are seen for Cheddar cheese fortified with 
vitamin D3, where the added vitamin is stable over 9 months 
of storage, while consumer tests show that the fortified prod-
uct is as acceptable as the unfortified one (33).
Regarding the heat stability of fortified products, heating 
of processed vitamin D3-fortified cheese for 3–5 min at 232 °C 
results in 25–30 % vitamin loss (32). However, by applying the 
same conditions (i.e. heating for 5 min at 232 °C) or heating for 
12 min at 100 °C, there is no loss of vitamin D3 observed in for-
tified low-fat or Cheddar cheese (31). Light can also be an is-
sue; vitamin D3-fortified and heat-treated low-fat milk stored 
in clear polyethylene terephthalate (PET) containers can lose up 
to 66 % of vitamin D3 during 12-week period; however, increas-
ing the pigmentation level in the PET formulation may decrease 
that loss to 35 % (34). Conversely, samples stored in the dark 
had a constant concentration of vitamin D3. In model systems, 
light-induced oxidation rate of vitamin D2 can be increased by 
riboflavin (35); on the other hand, by including microencapsu-
lated lycopene in skimmed milk, riboflavin-mediated photode-
gradation of vitamin D3 can be decreased by 45 % (36).
Taking all the aforementioned biotechnological issues into 
account, experience from European countries shows us that food 
fortification with vitamin D can be a relevant strategy to address 
the issue of its deficiency on a population level. In Finland, vi-
tamin D fortification of fat spreads and fluid milk products in a 
However, since vitamin D is unstable at higher temperatures, 
fat-soluble and relatively complex molecule, there are cer-
tain challenges in analysing its exact concentration in food 
products. More specifically, this attempt necessitates food 
matrix digestion and concomitant extraction from fat-solu-
ble components, extract clean-up and also a concentration 
step before the detection can be pursued. Analytical meth-
ods utilized to examine vitamin D in various foods include 
high pressure liquid chromatography (HPLC) and detection 
by ultraviolet absorption, mass spectrometry or a diode array 
detector (24). Currently used methods are all markedly similar, 
thus a demonstrated-performance method is used to assess 
their suitability (rather than defining a standard method) (24).
What we do know is that seafood, fish and eggs contain 
the highest concentration of vitamin D. Consequently, 100 % 
of vitamin D total daily needs can be covered by eating 100 g 
of salmon, cod fish or mackerel (25). These species also contain 
significant amount of omega-3 fatty acids; however, long-liv-
ing fish like tuna or salmon contain higher concentrations of 
mercury and other heavy metals, so the consumption should 
be cautiously moderate. Nowadays, fish liver oil can be found 
in the capsule form as one of the richest sources of vitamin 
D (25). Other nutrients containing vitamin D are milk, yogurt, 
egg yolks, shiitake mushrooms, cereals, oatmeal, fortified tofu, 
cheese, etc. Unfortunately, despite the variety of food that con-
tains vitamin D, intake by food is still very poor – therefore, edu-
cating people about healthy fats and promoting Mediterrane-
an diet can be appropriate steps towards solving this problem.
Until then, dietary supplements are often considered as a 
‘quick fix’, and ’total vitamin D intake‘ always reflects the joint 
dietary contribution from food sources and supplements (8). 
Such supplements are usually available in the form of pill, tab-
let, capsule, or some other controlled dosage form. Vitamin D 
present in them can be in either vitamin D2 or vitamin D3; how-
ever, the former is rarely used as the fortificant in dietary sup-
plements (26). The reason is that vitamin D3 shows approx. 87 
% more potency for raising (and maintaining) concentrations of 
25(OH)D in the serum and results in 2–3 times more storage of 
vitamin D than equimolar concentrations of vitamin D2 (27,28).
Recommended Dietary Allowance (RDA), which is a meas-
ure that aims to reflect an average level of dietary intake per day 
that is deemed sufficient for meeting nutrient requirements for 
vitamin D in basically all healthy individuals, varies depending 
on the age. Thus RDA is 400 international units (IU) or 10 μg in 
male and female infants (i.e. younger than 1 year of age), 600 
IU or 15 μg in all male and female individuals from 1 to 70 years 
of age, and 800 IU or 20 μg in those older than 70 years of age 
(8). It must be noted that, albeit sunlight may be considered a 
major source of vitamin D for certain people, RDAs of this vita-
min are established on the premise of minimal sun exposure.
FOOD FORTIFICATION WITH VITAMIN D
Fortifying foods with vitamin D is still not a very perva-
sive practice around the world. The United States and Canada 
have previously fortified food with vitamin D2 (29), and today 
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systematic way started in 2003 to improve vitamin D status (37). 
The study that investigated the effects of such policy on vitamin 
D status in this population found significant improvements dur-
ing the study period between 2000 and 2011 (37). In a population 
of Danish women with low vitamin D intake, low-dose vitamin 
D fortification of various foods has been touted as safe and ef-
fective population-based approach by Grønborg et al. (38). Sim-
ilarly, vitamin D fortification of wheat flour has been shown as a 
viable option for securely improving vitamin D intake and the 
overall status of various population groups at risk of deficiency 
in the United Kingdom – without increasing the risk of surpass-
ing present reference thresholds (39).
Some researchers caution how creative food-based solu-
tions are increasingly warranted to bridge the gap between 
current intake and required values of vitamin D, highlighting 
biofortification of wider range of foods (40). In short, food for-
tification with vitamin D has been touted as a possibly optimal 
way to increase intake due to its widest reach and population 
impact.
MICROBIOTA AND VITAMIN D
Gut microbiota consists of a large number of various bac-
terial species that are fluctuating during human lifetime (41). 
Even though bacterial colonisation begins at birth, nutri-
tion and lifestyle choices dictate its final composition. Fibre, 
as final product of digestion, is necessary for the production 
short-chain fatty acids (SCFAs) by bacteria residing in the gut. 
SCFAs (propionate, butyrate, or acetate) show a plethora of 
modulatory effects on the gastrointestinal system and metab-
olism (42). The connection between gut and brain is well es-
tablished, and it shows that SCFAs contribute to the synthesis 
of many neurotrasmitters. The most representative bacteria in 
gut microbiota are Bacteroidetes and Firmicutes, with higher 
ratio of Bacteroidetes. Vegan nutrition, rich in indigestible fi-
bre (such as inulin and galactooligosaccharides), favours the 
growth of Bacteroidetes; on the other hand, Western food full 
of refined carbohydrates and saturated fatty acids favours the 
growth of Firmicutes (43).
With its immunomodulatory role and the production of 
anti-inflammatory factors, vitamin D also exerts influence on 
the gut microbiota. Vitamin D receptor (VDR) is expressed on 
the intestinal epithelial cells, and it seems that SCFA butyrate 
increases its expression even more (44). Vitamin D is important 
for maintaining intestinal barrier integrity, thus its deficiency 
leads to dysbiosis and potential translocation of gut bacteria 
(45). The efficiency of vitamin D depends on the concentration 
and the ability of binding to VDR. Furthermore, the produc-
tion of bile acids is increased by regular consumption of West-
ern diet, which can adversely affect the availability of vitamin 
D in the gut; in addition, microbial disturbances are often cou-
pled with alterations in bile acid profiles of the host (46). More 
specifically, bile acids (like cholic and lithocholic acid) are li-
gands for VDR and, when bound to VDR, have the propensi-
ty to decrease the availability of vitamin D (43). A purported 
strong impact of vitamin D on the gut microbiota initiated 
studies about possible connection between maternal vitamin 
D status and newborn bacterial colonisation of the intestinal 
tract. Maternal supplementation of vitamin D and breast feed-
ing the infants resulted in lower burden of Clostridium difficile 
(47), which is a hazardous bacterial species that may give rise 
to pseudomembranous colitis and potentially fatal necrotiz-
ing enterocolitis in newborns.
A recent cross-sectional analysis from Brazil showed that 
systemic inflammation markers are highly dependent on the re-
lationship between the composition of gut microbiota and the 
concentration of vitamin D (48). In this study, Prevotella species 
were more abundant, while Veillonella and Haemophilus spe-
cies were less abundant in the subset of patients characterised 
by the highest vitamin D intake (48). Kanhere et al. (49) went one 
step further and conducted a randomized, double-blind, place-
bo-controlled clinical trial that aimed to assess gut and airway 
microbiota of patients with cystic fibrosis based on their vita-
min D status. This study has shown differential gut microbiota 
composition in patients with vitamin D insufficiency after 12-
week long treatment with either vitamin D3 or placebo, with 
Lactococcus numbers significantly higher in the former (i.e. vi-
tamin D3) group, and Erysipelotrichaceae and Veillonella more 
common in the latter (i.e. placebo) group (49). Furthermore, in 
an interventional pilot study, Bashir et al. (50) showed how vi-
tamin D3 has the ability to modulate the microbiome of the 
upper GI tract, with increased bacterial richness and decreased 
abundance of Gammaproteobacteria. All these data demon-
strate that vitamin D can indeed regulate the gut microbiome 
and that either vitamin D or VDR deficiency may result in dys-
biosis, opening the door for subsequent gut injuries and an ar-
ray of different diseases.
INFLAMMATORY BOWEL DISEASES AND VITAMIN D
IBD can be seen as an umbrella term for idiopathic, relaps-
ing and remitting inflammatory diseases of gastrointestinal 
tract which include Crohn’s disease (CD) and ulcerative coli-
tis (UC) (51). The aetiology of IBD is multifactorial, but it is in 
part due to the deregulation of the immune response to vari-
ous environmental factors, coupled with a pre-existing genet-
ic predisposition (52). Both diseases commonly affect young 
people as a result of aberrant mucosal immune response in 
genetically susceptible individuals. In Croatia the incidence 
of UC and CD is 4.3/100 000 and 7/100 000, respectively (53). 
There are many risk factors affecting IBD, but smoking is the 
only one proved with a sort of two-faced effect, increasing the 
risk for CD and reducing the risk for UC (54,55). In CD a trans-
mural granulomatosis inflammation can be found in any part 
of GI system, although in 70 % cases terminal ileum is affect-
ed. On the other hand, UC affects colonic mucosa and in a 
majority of cases causes proctitis (56). Both diseases manifest 
with episodic or chronic diarrhoea, crampy abdominal dis-
comfort and systemic symptoms (fever, mass loss and/or ma-
laise) (56). If there is a mixed group of abdominal symptoms 
without any organic cause, and all other diseases are exclud-
ed, we can diagnose irritable bowel syndrome (IBS). When the 
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inflammation affects microvilli, there is a reduced ability of ab-
sorption in the intestine. Malabsorption in patients with IBD 
almost invariably leads to hypovitaminosis D. Large studies 
have shown that more than 60 % of patients with IBD have 
inadequate concentration of vitamin D (57). When compared 
to healthy population without IBD, the prevalence of hypo-
vitaminosis is quite similar to patients with IBD. Also, it has 
been shown that solar UVB exposure reduces risk of IBD based 
on results from ecological studies (58,59). Hence we pose the 
question – is it possible that hypovitaminosis D triggers IBD, 
or is it only a secondary result of the disease?
Plenty of different research endeavours aimed to answer 
that pertinent query. From an immunological perspective, vi-
tamin D regulates the immune system and calcitriol appears 
to play a role in the development of self-tolerance. It decreas-
es Th1-driven autoimmune response by regulating T helper cell 
and dendritic cell function (60). Th1 autoimmune response rep-
resents the main inflammation pathway in patients with CD, 
while Th1 cells produce proinflammatory cytokines (including 
IFN-γ, IL-2 and TNF-α). In vitro studies with calcitriol show the 
important role in reducing the production of proinflammatory 
cytokines and promoting T helper/Th2 regulatory responses to 
produce anti-inflammatory interleukin (IL)-4. Patients with UC 
have suppressed Th2 inflammatory response in general, while 
evidence points to a plethora of beneficial effects on the gut 
immune system (Table 1; (61)). Strong in vitro evidence of im-
munomodulatory vitamin D effects instigated human studies 
with vitamin D supplements in IBD, which have shown that vita-
min D supplementation in IBD patients improves inflammatory 
bowel disease outcomes by inducing or maintaining remission, 
and improving quality of life scores (62).
Table 1. A summary of physiological effects of vitamin D on the gut 
immune system according to Gubatan and Moss (61); reduced levels 
of vitamin D can affect all of the functions
 Protection of the integrity of the intestinal epithelial barrier
  Reduced epithelial cell injury induced by Escherichia coli or 
lipopolysaccharide
 Differential regulation of intestinal tight junction proteins
 Suppression of gut epithelial cell apoptosis
 Stimulation of NOD2/CAR15 expression
  Increase in antimicrobial peptides such as defensins and 
cathelidicin
  Proliferation control of CD8+ T cells involved in intestinal 
inflammation
 Inhibition of proinflammatory Th1 and Th17 cells
 Down-regulation of interleukin-23 receptor pathway
 General promotion of intestinal immune tolerance
It must be noted that clinical trials in humans that have 
interrogated the role of vitamin D axis in IBD are regularly het-
erogeneous regarding their overall design and methods used, 
hampering in turn the comparability of research findings (Ta-
ble 2; (51-55,57,58)). Still, most of those studies share common 
points of agreement on the benefits of vitamin D supplemen-
tation regarding disease outcomes and achieved quality of 
life (63). For example, randomized trials on CD patients have 
shown that high doses of vitamin D3 supplementation (up to 
10 000 IU per day) may substantially decrease clinical relapse 
rates (64,65), and some other studies even hinted how vita-
min D supplementation (particularly in its active form) may 
result in short-term beneficial impact on disease activity (66). 
Similar results were found in patients with UC, where vita-
min D supplementation (especially in high doses) resulted 
in diminished disease activity, better scores assessing symp-
tom-based activity, as well as significantly improved quality 
of life (67,68). Suboptimal levels of 25-hydroxy-vitamin D in 
circulation are frequently seen in IBD and are associated with 
the risk of flairs, inadequate response to drugs, more common 
hospitalisations and surgeries, low bone mineral density, as 
well as deterioration of life quality (56). This is also substantiat-
ed by a very recent study where many researchers addressed 
vitamin D deficiency in a European IBD inception cohort (also 
known as Epi-IBD study) (69). In a total of 238 patients that 
were recruited between 2010 and 2011, they demonstrated 
high prevalence of vitamin D deficiency in treatment-naive 
European populations with IBD, and also highlighted low vi-
tamin D levels in patients who smoke. Such large efforts may 
open the door to consider food fortification with vitamin D 
as a viable strategy.
A shift of the composition of intestinal microbiota is prob-
ably implicated in adverse disease outcomes as well. For ex-
ample, in a recent prospective controlled interventional study 
in Germany, Schäffler et al. (70) showed that the microbial 
communities found in CD patients were significantly altered 
during early vitamin D administration when compared to 
healthy controls. By analysing highly abundant species, they 
concluded that the vitamin D supplementation may be a har-
binger of positive effects in CD – not only by modulating in-
testinal bacterial flora, but also by expanding the abundance 
of potentially beneficial bacterial species (70). Such microbial 
perturbations are supplemented by beneficial immune mod-
ulation that is also prompted by vitamin D supplementation; 
for example, it has been shown that vitamin D3 in CD patients 
may reduce cytokine production (most notably IL-1β, IL-6 and 
IL-10) and monocyte-derived dendritic cell maturation (71). 
Although the optimal protocol of vitamin D supplementation 
in patients with IBD is still not straightforward, recommended 
blood concentrations of vitamin D in this population are be-
tween 75 and 125 nmol/L, with daily doses ranging between 
1800 and 10 000 IJ (6). These values proved to be safe and 
beneficial in active forms of the disease.
CD and UC cannot be considered diseases of vitamin D de-
ficiency sensu stricto; however, their pathogenesis is evidently 
closely related to vitamin D at cellular and phenotypic levels. 
Due to the complex relationship of vitamin D and IBD, it is ex-
tremely hard to unequivocally establish causation, and for more 
significant results future intervention trials should include larg-
er cohorts of patients. For now, both theoretical and empirical 
support is solid enough to claim vitamin D indeed plays a sub-
stantial role in ameliorating disease parameters in patients with 
CD and UC (Table 2). It is thus of utmost importance to focus 
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on adequate vitamin D levels during asymptomatic periods of 
the disease in further interventions, while at the same time in-
vestigate potential synergistic effects with present and future 
treatment modalities. Regarding the latter, it should be empha-
sised that vitamin D3-containing nanostructured lipid carriers 
have already been explored as an alternative mode of treating 
IBD (72). Additional treatment approaches at the microbiome 
level represent promising opportunities towards balanced gut 
microbiota and improved IBD symptoms (73).
CONCLUSIONS
Vitamin D in immune-mediated disorders seems to be 
closely linked to bacterial composition and their metabo-
lism, as chronic intestinal dysbiosis in compromised condi-
tions may cause vitamin D receptor dysfunction and thus 
trigger a vicious cycle that finally results in diseased state. A 
growing base of evidence supports the concept of intricate 
relationship between gut dysbiosis and vitamin D metabo-
lism, which holds the potential of discovering new pathogen-
ic mechanisms and increasing treatment options at our dis-
posal. The research has shown how vitamin D insufficiency 
can be associated with gut microbiota alterations that may 
boost inflammation processes; therefore, impacting microbi-
al composition with vitamin D supplementation may bring 
substantial benefits to the affected individuals. For now, there 
are still some gaps that prevent the inclusion of recommenda-
tions on manipulating vitamin D axis and gut microbiome into 
the guidelines for clinical practice; however, recent research 
is quite encouraging in instituting higher doses of vitamin D 
as one of the complementary approaches to our therapeutic 
armamentarium in IBD. In conclusion, although the answer 
to the question whether there is a therapeutic and preven-
tive potential of vitamin D supplementation and food fortifi-
cation in patients with CD and UC is still not straightforward, 
it is steadily moving towards a favourable ’yes’.
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